A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 331-335

  Hoffer, Erica ^a   Akria, Luiza ^a   Tabak, Arek ^a   Scherb, Inna ^a   Rowe, Jacob M ^a   Krivoy, Norberto ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Area under the curve (AUC); Bone marrow transplantation (BMT); Busulfan; Dose adjustment

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIVER TOXICITY; MALE; MATHEMATICAL MODEL; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; BUSULFAN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 2542592386     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00019     Document Type: Article

References (11)

1. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non-lymphocytic leukaemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353.
2. Parkman R, Rappeport JM, Hellman S, et al. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation. Blood. 1984;64:852-857.
3. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
4. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
5. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
6. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055-3060.
7. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000;25:925-930.
8. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
9. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment in pediatric patients undergoing bone marrow transplantation. Marrow Transplant. 2001;11:1013-1018.
10. Hassan M, Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr. 1983;14:374-380.
11. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477-485.